Want to see TECX full AI Analyst Report?
TECX Stock Chart & Stats
$30.37
-$1.24(-3.92%)
At close: 4:00 PM EDT
$30.37
-$1.24(-3.92%)
Day’s Range― - ―
52-Week Range$14.39 - $39.53
Previous Close$30.37
Volume99.11K
Average Volume (3M)178.91K
Market Cap
$735.64M
Enterprise Value$429.22
Total Cash (Recent Filing)$227.07M
Total Debt (Recent Filing)$4.40M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 05, 2026EPS Estimate
-1.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.57
Shares Outstanding19,549,366
10 Day Avg. Volume173,306
30 Day Avg. Volume178,909
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$79.71Price Target Upside162.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger Capital BaseMinimal debt reduces fixed financial obligations and gives Tectonic greater flexibility to fund research. The improved equity base also provides a stronger platform for advancing clinical programs, although ongoing losses will continue to consume capital.
TX45 Phase 2 Enrollment CompletedCompleting enrollment removes a major execution hurdle and advances TX45 toward a meaningful clinical readout. Positive data could support further development and strengthen the company’s position in pulmonary hypertension associated with HFpEF.
Exposure To A High-unmet-need MarketTargeting pulmonary hypertension linked to HFpEF gives Tectonic exposure to a clinically important area where effective treatments may have substantial value. This market focus can support durable development relevance if TX45 demonstrates meaningful benefit.
Bears Say
No Commercial RevenueTectonic remains entirely dependent on clinical progress and future financing because it has not established a commercial revenue stream. This limits operating visibility and leaves future value heavily reliant on successful development and potential commercialization.
Accelerating Cash BurnSustained and increasing cash consumption raises the likelihood that Tectonic will need additional capital before generating revenue. Future funding requirements could dilute shareholders or constrain the pace and scope of clinical development.
Widening Net LossesLosses are expanding as Tectonic increases spending ahead of commercialization, while revenue remains absent. Persistent negative returns and limited earnings visibility make it difficult to demonstrate operating leverage until a candidate reaches later-stage development or the market.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic Inc’s price range in the past 12 months?
Tectonic Therapeutic Inc lowest stock price was $14.38 and its highest was $39.53 in the past 12 months.
What is Tectonic Therapeutic Inc’s market cap?
Tectonic Therapeutic Inc’s market cap is $735.64M.
When is Tectonic Therapeutic Inc’s upcoming earnings report date?
Tectonic Therapeutic Inc’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Tectonic Therapeutic Inc’s earnings last quarter?
Tectonic Therapeutic Inc released its earnings results on Aug 06, 2026. The company reported -$1.18 earnings per share for the quarter, beating the consensus estimate of -$1.349 by $0.169.
Is Tectonic Therapeutic Inc overvalued?
According to Wall Street analysts Tectonic Therapeutic Inc’s price is currently Undervalued.
Does Tectonic Therapeutic Inc pay dividends?
Tectonic Therapeutic Inc does not currently pay dividends.
What is Tectonic Therapeutic Inc’s EPS estimate?
Tectonic Therapeutic Inc’s EPS estimate is -1.32.
How many shares outstanding does Tectonic Therapeutic Inc have?
Tectonic Therapeutic Inc has 19,549,366 shares outstanding.
What happened to Tectonic Therapeutic Inc’s price movement after its last earnings report?
Tectonic Therapeutic Inc reported an EPS of -$1.18 in its last earnings report, beating expectations of -$1.349. Following the earnings report the stock price went up 2.515%.
Which hedge fund is a major shareholder of Tectonic Therapeutic Inc?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.71 (162.48% Upside)
$79.71 (162.48% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 19.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.73%
Trailing 12-Months
Company Description
Tectonic Therapeutic Inc
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$79.71
▲(162.48% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
34.38% Insiders
14.50% Mutual Funds
29.81% Other Institutional Investors
14.97% Public Companies and
Individual Investors